Foghorn Therapeutics (FHTX) outlined its objectives for 2025 on Monday, including advancing its inhibitor and degrader program trials.
The company said it will continue to enroll and dose patients in a phase 1 trial of FHD-909 to treat solid tumors. It will also present preclinical combination data for FHD-909 with pembrolizumab and KRAS inhibitors at the American Association for Cancer Research's annual meeting in April, the company said.
"We are continuing to advance our Selective CBP degrader and our Selective EP300 degrader, which are both implicated in a wide range of cancers," Chief Executive Adrian Gottschalk said in a statement.
Foghorn said that as of the end of 2024, it had $243.8 million cash, cash equivalents and marketable securities that will provide a cash runway into 2027.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。